Edition:
United Kingdom

Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

2.43USD
22 Feb 2019
Change (% chg)

$0.14 (+6.11%)
Prev Close
$2.29
Open
$2.43
Day's High
$2.43
Day's Low
$2.43
Volume
274
Avg. Vol
3,333
52-wk High
$5.70
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Oasmia Pharmaceutical Announces Change In The Number Of Shares And Votes In Company
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Oasmia Pharmaceutical AB ::OASMIA PHARMACEUTICAL - IN TOTAL CIRCA SEK 7 MILLION OF CONVERTIBLE LOAN DURING JANUARY, AT REQUEST OF CONVERTIBLE LOAN HOLDERS, CONVERTED INTO SHARES.OASMIA PHARMACEUTICAL - WITH CONVERSION, TOTAL NUMBER OF SHARES AND VOTES IN CO HAVE IN JAN 2019 INCREASED WITH 1.43 MILLION SHARES AND VOTES.AS OF 31 JAN, TOTAL NUMBER OF SHARES AND VOTES IN OASMIA ARE 201.95 MILLION SHARES AND VOTES.  Full Article

Change In Number Of Shares And Votes In Oasmia Pharmaceutical AB
Friday, 30 Nov 2018 

Nov 30 (Reuters) - :CHANGE IN NUMBER OF SHARES AND VOTES IN OASMIA PHARMACEUTICAL AB (PUBL).OASMIA PHARMACEUTICAL -IN TOTAL CIRCA MSEK 21.3 OF CONVERTIBLE LOANS HAVE DURING NOVEMBER 2018 CONVERTED INTO SHARES.OASMIA PHARMACEUTICAL AB -NOW TOTAL NUMBER OF SHARES AND VOTES IN COMPANY HAVE IN NOVEMBER INCREASED WITH 4,115,204 SHARES AND VOTES.OASMIA PHARMACEUTICAL -SHARE CAPITAL HAS INCREASED WITH SEK 411,520.40.  Full Article

Oasmia Pharmaceutical Q2 Operating Loss At SEK 22.6 Mln
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Oasmia Pharmaceutical AB ::REG-OASMIA PHARMACEUTICAL AB (PUBL) INTERIM REPORT FOR THE PERIOD MAY – OCTOBER 2018.Q2 CONSOLIDATED NET SALES AMOUNTED TO TSEK 158 COMPARED TO TSEK 1,651 IN Q2 PREVIOUS YEAR.Q2 OPERATING LOSS WAS TSEK 22,627 COMPARED TO TSEK 22,129 IN Q2 PREVIOUS YEAR.  Full Article

Oasmia Pharmaceutical Signs Manufacturing Deal With Baxter Oncology
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Oasmia Pharmaceutical AB ::ANNOUNCES NEW AGREEMENT WITH BAXTER ONCOLOGY GMBH FOR GLOBAL COMMERCIAL MANUFACTURING OF APEALEA.TERMS OF AGREEMENT WERE NOT DISCLOSED.SIGNED A NEW FIVE-YEAR CONTRACT WITH BAXTER BIOPHARMA SOLUTIONS.FIVE-YEAR CONTRACT WITH BAXTER BIOPHARMA SOLUTIONS FOR GLOBAL COMMERCIAL MANUFACTURING OF APEALEA.  Full Article

Oasmia Pharmaceutical Approved For Apealea In EU
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - Oasmia Pharmaceutical AB ::REG-OASMIA PHARMACEUTICAL RECEIVES APPROVAL FROM EUROPEAN COMMISSION FOR APEALEA® (PACLITAXEL MICELLAR) IN THE EUROPEAN UNION.APEALEA IS APPROVED IN EUROPEAN UNION FOR TREATMENT OF PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER.  Full Article

Oasmia Pharmaceutical: New US Patent Granted
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Oasmia Pharmaceutical AB ::NEW U.S. PATENT RELATED TO OASMIA PHARMACEUTICAL’S NANOTECHNOLOGY PLATFORM XR17 HAS BEEN GRANTED.PATENT WILL BE VALID THROUGH 2036..PATENT WILL BE PUBLISHED ON NOVEMBER 27(TH), 2018..OASMIA PHARMACEUTICAL - UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HAS ISSUED A NOTIFICATION OF ALLOWANCE OF A PATENT.  Full Article

Oasmia Pharmaceutical Granted US Patent Related To Nanotechnology Platform XR17
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - OASMIA PHARMACEUTICAL AB ::REG-NEW U.S. PATENT RELATED TO OASMIA PHARMACEUTICAL’S NANOTECHNOLOGY PLATFORM XR17 HAS BEEN GRANTED.PATENT WILL BE PUBLISHED ON NOVEMBER 27(TH), 2018..PATENT WILL BE VALID THROUGH 2036..  Full Article

Oasmia says Phase II study with Doxophos well tolerated
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - Oasmia Pharmaceutical AB says::Overall response rate data from the (RXE(1)) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated..Assessment is that the positive safety and efficacy data will be sufficient for AdvaVet Inc. to seek conditional approval for Doxophos Vet in the US in the first half of 2019..  Full Article

Oasmia Pharma Q1 operating loss narrows slightly yr/yr
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Oasmia Pharmaceutical AB ::Q1 CONSOLIDATED NET SALES AMOUNTED TO TSEK 128 COMPARED TO TSEK 20 IN Q1 PREVIOUS YEAR.SAYS OPERATING LOSS WAS TSEK 26,572 COMPARED TO TSEK 28,421 IN Q1 PREVIOUS YEAR.  Full Article

Oasmia Pharmaceutical Says May Offer, Issue, Sell Up to US$25 Mln Shares
Monday, 30 Apr 2018 

April 30 (Reuters) - Oasmia Pharmaceutical AB ::OASMIA PHARMACEUTICAL AB -MAY OFFER, ISSUE, SELL UP TO US$25 MILLION OF SHARES/ADSS, NUMBER OF WARRANTS TO PURCHASE ORDINARY SHARES, COMBINATION OF SECURITIES.  Full Article